Engineered Factor H Variant for Sustained Complement Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for complement-mediated diseases, such as PNH and aHUS, require frequent and inconvenient IV dosing and risk compromising host defense by blocking the alternative or terminal complement pathways.
Innovation Solution
A recombinant vector expressing an engineered human complement regulator factor H (fH) protein variant, specifically designed to retain complement regulatory function and provide long-lasting therapeutic effects, is administered to treat complement-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches (monoclonal antibodies, peptides, small molecules) are used to block complement pathways, then complement-mediated diseases are treated, but frequent IV dosing is required and host defense is compromised
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of complement regulation by using recombinant factor H protein with engineered properties (extended half-life, enhanced stability) to achieve sustained therapeutic levels in the bloodstream, eliminating the need for frequent dosing while maintaining continuous complement pathway regulation
Solution Approach 2:
The recombinant factor H protein functions as a self-regulating therapeutic agent that continuously binds to complement components (C3b, C4b) and regulates the alternative and classical pathways without requiring external re-dosing, effectively serving itself by maintaining therapeutic activity through its extended half-life properties
2Object-affected harmful factors
If complement pathways are blocked to treat disease, then complement-mediated tissue injury is prevented, but host defense capabilities are compromised
Solution Approach 1:
The recombinant factor H protein provides localized regulation of complement activation at specific sites (fluid phase and cell surfaces) where it binds to complement components, allowing selective inhibition of pathological complement activation while preserving complement-mediated host defense functions in other contexts
Solution Approach 2:
The recombinant factor H acts as an intermediary molecule that modulates complement activation by binding to C3b and C4b, providing controlled regulation of the complement cascade that prevents excessive tissue injury while maintaining sufficient complement activity for host defense against pathogens
3Duration of action of moving object
If recombinant factor H protein is used to treat complement disorders, then therapeutic duration is extended to at least a month, but protein stability and half-life must be significantly increased
Solution Approach 1:
The patent engineers recombinant factor H protein with modified amino acid sequences and structural properties that increase its serum half-life and stability, allowing the protein to maintain therapeutic levels in the bloodstream for at least a month following single or limited dosing
Solution Approach 2:
The recombinant factor H protein is produced as a genetically engineered composite molecule that combines native factor H domains with modified regions that enhance stability and half-life, creating a hybrid protein structure with improved pharmacokinetic properties for sustained therapeutic effect
Data Source
AI summary
Disclosed herein are factor H variants, vectors comprising said factor H variants, and pharmaceutical compositions comprising the same for treatment of disorders.